CLINICAL TRIALS PROFILE FOR VALOPICITABINE
✉ Email this page to a colleague
Clinical Trials for Valopicitabine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00118768 ↗ | A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C | Completed | Merck Sharp & Dohme Corp. | Phase 2 | This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection). |
| NCT00120835 ↗ | Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C | Completed | Merck Sharp & Dohme Corp. | Phase 1/Phase 2 | This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is also evaluating the ability of valopicitabine to decrease the amount of hepatitis C virus in the body. The results for patients taking valopicitabine alone will be compared with the results for patients taking valopicitabine together with pegylated interferon. |
| NCT00120861 ↗ | Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy | Completed | Merck Sharp & Dohme Corp. | Phase 2 | This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection. |
| NCT00395421 ↗ | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | Completed | Novartis Pharmaceuticals | Phase 2 | This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection. |
| NCT00395421 ↗ | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | Completed | Merck Sharp & Dohme Corp. | Phase 2 | This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Valopicitabine
Condition Name
Clinical Trial Locations for Valopicitabine
Trials by Country
Clinical Trial Progress for Valopicitabine
Clinical Trial Phase
Clinical Trial Sponsors for Valopicitabine
Sponsor Name
